Vabysmo label expanded

A blocked vein in the eye can leave the retina swollen like a sponge, and that swelling can blur central vision for months. On April 9, 2026, the Food and Drug Administration cleared Vabysmo for treating that swelling after the first six months, instead of stopping the label there. (fda.gov) (gene.com) The condition is called macular edema following retinal vein occlusion. The macula is the small center of the retina that handles sharp reading vision, and when fluid collects there, straight lines can look bent and faces can lose detail. (nei.nih.gov) (fda.gov) Vabysmo is injected into the eye and works by blocking two leak-driving signals, vascular endothelial growth factor A and angiopoietin 2. Most older retina drugs in this category block only vascular endothelial growth factor, which is one reason Vabysmo has been watched closely for how long patients can go between shots. (gene.com) (roche.com) When the Food and Drug Administration first added retinal vein occlusion to Vabysmo’s label in October 2023, the dosing language in the prescribing information said 6 milligrams every 4 weeks for 6 months. That meant doctors could still use it longer in practice, but the official label had not yet caught up to longer follow-up data. (fda.gov) (gene.com) The evidence behind the update came from two large phase 3 studies called BALATON and COMINO. BALATON enrolled patients with branch retinal vein occlusion, while COMINO enrolled patients with central or hemiretinal vein occlusion, which are usually the more severe blockages. (fda.gov) (ophthalmologyscience.org) Those trials enrolled more than 1,280 treatment-naive patients, then followed them into a longer dosing phase after the first 24 weeks. By week 72, vision gains and retinal drying were maintained, and nearly 60% of patients in BALATON and up to 48% in COMINO were extended to injections every 3 or 4 months. (roche.com) (ophthalmologyretina.org) That is the practical change in this label update. It turns “monthly for 6 months” into a label that now recognizes continued treatment beyond month 6, which gives retina clinics and insurers firmer paperwork for the way many patients are actually managed over time. (gene.com) (retinalphysician.com) The update does not make the drug risk-free. The prescribing information for Vabysmo already warns about eye infection inside the eyeball, retinal detachment, temporary pressure spikes, and a 2024 warning addition for retinal vasculitis or retinal vascular occlusion. (gene.com) (fda.gov) For Genentech, the win is not a brand-new disease approval but something more administrative and immediate. A label change like this forces updates across physician materials, safety language, reimbursement documents, medical information responses, and field guidance so every sentence matches the new Food and Drug Administration wording. (gene.com) (healio.com) The larger pattern is that eye-drug labels are no longer frozen on the day of first approval. Vabysmo was first approved in the United States in 2022, gained the retinal vein occlusion indication in 2023, and now in 2026 has a more explicit long-term use label built from follow-up data that took another two years to mature. (fda.gov 1) (fda.gov 2) (gene.com)